Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jun 28:13:22.
doi: 10.1186/s13027-018-0195-4. eCollection 2018.

Plasmablastic lymphoma in Malawi

Takondwa Zuze  1 , Matthew S Painschab  1   2 , Ryan Seguin  1   2 , Evarista Kudowa  1 , Bongani Kaimila  1 , Edwards Kasonkanji  1 , Tamiwe Tomoka  1   3 , Bal Mukunda Dhungel  1   2 , Maurice Mulenga  4 , Maria Chikasema  1 , Blessings Tewete  1 , Asekanadziwa Ntangwanika  1 , Sarah Chiyoyola  1 , Fred Chimzimu  1 , Coxcilly Kampani  1 , Robert Krysiak  1   2 , Nathan D Montgomery  2 , Yuri Fedoriw  2 , Satish Gopal  1   2   3
Affiliations

Plasmablastic lymphoma in Malawi

Takondwa Zuze et al. Infect Agent Cancer. .

Abstract

Plasmablastic lymphoma (PBL) clinical descriptions are scarce from sub-Saharan Africa (SSA) where both HIV and EBV are highly endemic. We identified 12 patients with pathologically confirmed PBL from a prospective cohort in Lilongwe, Malawi. Median age was 46 (range 26-71), seven (58%) were male, and six (50%) were HIV-positive. Eight patients were treated with CHOP and four with a modified EPOCH regimen. One-year overall survival was 56% (95% CI 24-79%), without clear differences based on HIV status. PBL occurs in Malawi in HIV-positive and HIV-negative individuals and can be treated successfully with curative intent, even in a low-resource setting in SSA.

Keywords: EBV; EPOCH; HIV; Plasmablastic lymphoma; Sub-Saharan Africa.

PubMed Disclaimer

Conflict of interest statement

All patients provided written informed consent for participation in the Kamuzu Central Hospital Lymphoma Study, which was approved by the Malawi National Health Sciences Research Committee (1107) and University of North Carolina Biomedical Institutional Review Board (12–2255).Not applicableThe authors declare that they have no competing interests.Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Overall survival of plasmablastic lymphoma patients in Lilongwe stratified by HIV status. No difference was found between HIV+ and HIV- patients by log-rank test
See this image and copyright information in PMC

References

    1. STEIN & H. Plasmablastic lymphoma: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues; 2008. p. 256–7. https://ci.nii.ac.jp/naid/10027382444/ Accessed 8 Feb 2018
    1. Carbone A. AIDS-related non-Hodgkin’s lymphomas: from pathology and molecular pathogenesis to treatment. Hum Pathol. 2002;33:392–404. doi: 10.1053/hupa.2002.124723. - DOI - PubMed
    1. Han X, Duan M, Hu L, Zhou D, Zhang W. Plasmablastic lymphoma: review of 60 Chinese cases and prognosis analysis. Medicine. 2017;96:e5981. doi: 10.1097/MD.0000000000005981. - DOI - PMC - PubMed
    1. Choi S-Y, Cho Y-A, Hong S-D, Lee J-I, Hong S-P, Yoon H-J. Plasmablastic lymphoma of the oral cavity in a human immunodeficiency virus-negative patient: a case report with literature review. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014;117:e115–e120. doi: 10.1016/j.oooo.2013.04.017. - DOI - PubMed
    1. Ferrazzo K, Mesquita R, Aburad A, Nunes F, de Sousa S. EBV detection in HIV-related oral plasmablastic lymphoma. Oral Dis. 2007;13:564–569. doi: 10.1111/j.1601-0825.2006.01336.x. - DOI - PubMed

LinkOut - more resources